Santaris Q1 Loss Narrows, Completes Phase I Trial of miRNA HCV Rx

The company also said that it expects to launch another phase I trial of the microRNA-targeting drug later in the year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.